Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc ...

Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...

This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...

This paper describes Unbend - a new method for measuring and correcting motions in cryo-EM images, with a particular emphasis on more challenging in situ samples such as lamella and whole cells. The ...